Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin

V. L. Serebruany, A. H. Glassman, A. I. Malinin, D. Atar, D. C. Sane, B. R. Oshrine, J. J. Ferguson, C. M. O'Connor

Research output: Contribution to journalArticle

Abstract

Clinical depression has been identified as an independent risk factor for increased mortality in patients with coronary artery disease. Enhanced platelet activity has been suggested as the mechanism responsible for this adverse association. Selective serotonin reuptake inhibitors (SSRIs) are known to inhibit platelets in patients undergoing coronary stenting. We sought to determine whether concomitant therapy with SSRIs would yield additional anti-platelet benefit in patients with congestive heart failure (CHF) already treated with antecedent aspirin. A total of 88 patients with left ventricular ejection fraction (LVEF)

Original languageEnglish (US)
Pages (from-to)517-521
Number of pages5
JournalEuropean Journal of Heart Failure
Volume5
Issue number4
DOIs
StatePublished - Aug 2003

Keywords

  • Congestive heart failure
  • Platelets
  • Selective serotonin reuptake inhibitors (SSRIs)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin'. Together they form a unique fingerprint.

  • Cite this